Search - tctmd.com

Displaying 201 - 220 of 807

Sort: Relevancy | Date

Presentation TCT 2018

Most Frequent Errors I See in the Analysis and Interpretation of Trials

Presenter: Peter Juni, Robert W. Yeh

September 23, 2018

Presentation TCT 2018

How to Make Trials Larger, Simpler and Less Expensive

Presenter: Peter Juni, Robert W. Yeh, Matthew T. Roe

September 23, 2018

Presentation TCT 2018

LEADERS FREE II: Summary and Clinical Implications

Presenter: Andreas Baumbach, Stephan Windecker, Mitchell W. Krucoff

September 23, 2018

Presentation TCT 2018

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Presenter: Deepak L. Bhatt, Tullio Palmerini, Michael Maeng

September 23, 2018

Presentation TCT 2018

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Philip M. Urban

September 23, 2018

Presentation TCT 2018

Transcatheter Mitral Valve Replacement: Trial Design Considerations

Presenter: Michael J. Mack, Changfu Wu, John C Laschinger

September 23, 2018

Presentation TCT 2018

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Usman Baber

September 23, 2018

Presentation TCT 2018

Sham Controlled Trials for Devices Are Unethical, Unfeasible, and Unnecessary!

Presenter: Ajay J. Kirtane, Stuart J. Pocock, William F. Fearon

September 23, 2018

Presentation TCT 2018

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Sham Controlled Trials Should Be the New Gold Standard for Device Trials!

Presenter: Ajay J. Kirtane, Stuart J. Pocock, Bernard J. Gersh

September 23, 2018

Presentation TCT 2018

ORBITA in the Spotlight: How I Would Have Done the Trial Differently

Presenter: Ajay J. Kirtane, Stuart J. Pocock

September 23, 2018

Presentation TCT 2018

ORBITA in the Spotlight: How I Interpret ORBITA as an Interventional Cardiologist

Presenter: Ajay J. Kirtane, Stuart J. Pocock, Rasha Al-Lamee

September 23, 2018

Presentation TCT 2018

Aortic Arch Aneurysm: Management and Treatment Options With Case Examples

Presenter: Robert A. Lookstein, Virendra I Patel, Nimesh Desai

September 23, 2018

Presentation TCT 2018

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

Presenter: E. Magnus Ohman, Stuart J. Pocock

September 23, 2018

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

Presentation TCT 2018

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

Presenter: E. Magnus Ohman, Stuart J. Pocock, David J. Maron

September 23, 2018

Presentation TCT 2018

Composite Endpoints: When Are They Valid and When Should They Be Discarded

Presenter: E. Magnus Ohman, Stuart J. Pocock, Sanjay Kaul

September 23, 2018

News Conference News TCT 2018

CTO PCI Patients With CKD Have More Acute Kidney Injury but Not Dialysis or TLF Over 2 Years

Yael L. Maxwell

September 23, 2018

Presentation TCT 2018

4-Tech TriCinch Enhanced Design - Technology and Clinical Updates

Presenter: Paolo Denti

September 23, 2018

News Conference News TCT 2018

COAPT: MitraClip Reduces Repeat Hospitalizations, Mortality in Functional MR Patients With Severe HF

Shelley Wood

September 23, 2018

Advertisement

Most Frequent Errors I See in the Analysis and Interpretation of Trials

How to Make Trials Larger, Simpler and Less Expensive

LEADERS FREE II: Summary and Clinical Implications

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Transcatheter Mitral Valve Replacement: Trial Design Considerations

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Sham Controlled Trials for Devices Are Unethical, Unfeasible, and Unnecessary!

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Sham Controlled Trials Should Be the New Gold Standard for Device Trials!

ORBITA in the Spotlight: How I Would Have Done the Trial Differently

ORBITA in the Spotlight: How I Interpret ORBITA as an Interventional Cardiologist

Aortic Arch Aneurysm: Management and Treatment Options With Case Examples

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

High Mortality but Durable Results With Valve-in-Valve TAVR

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

Composite Endpoints: When Are They Valid and When Should They Be Discarded

CTO PCI Patients With CKD Have More Acute Kidney Injury but Not Dialysis or TLF Over 2 Years

4-Tech TriCinch Enhanced Design - Technology and Clinical Updates

COAPT: MitraClip Reduces Repeat Hospitalizations, Mortality in Functional MR Patients With Severe HF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content